Sign Up to like & get
recommendations!
1
Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.6_suppl.278
Abstract: 278Background: Tivozanib (T) is a potent and highly selective VEGF receptor (R) tyrosine kinase inhibitor in clinical development for RCC. Axitinib is also a potent and selective VEGF-R inhibitor n...
read more here.
Keywords:
patients advanced;
renal cell;
tivozanib patients;
axitinib ... See more keywords